OMLEYA
Live / Allowed — Fifth extension granted (statement of use) (as of 15 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 May 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 98012789
- Mark type
- Word mark
- Filed
- 25 May 2023
- Published for opposition
- 17 Oct 2023
- Attorney of record
- Kelley B. Harrington
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; biologics for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders
Owner
- Omeros Corporation, Seattle, WA, US
- Omeros Corporation, Seattle, WA, US
Prosecution history
- 15 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Aug 2026 — SOU EXTENSION 5 GRANTED
- 27 May 2026 — SOU EXTENSION 5 FILED
- 14 Aug 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 27 May 2026 — SOU TEAS EXTENSION RECEIVED
- 18 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Nov 2025 — SOU EXTENSION 4 GRANTED
- 17 Nov 2025 — SOU EXTENSION 4 FILED
- 17 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Apr 2025 — SOU EXTENSION 3 GRANTED
- 07 Apr 2025 — SOU EXTENSION 3 FILED
- 07 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 14 Nov 2024 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 14 Nov 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED